CA
NZ
UK
AU
IND
US
Sotera Health Company (NASDAQ: SHC) delivered a strong second quarter with adjusted earnings per share of $0.26, surpassing the consensus estimate of $0.24. The company's net revenues surged 9.2% year-over-year, bolstered by performance across its business units. This strong financial footing laid the groundwork …
Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) reported impressive financial results for the second quarter, achieving $173.9 million in net product sales from XDEMVY. This marks an increase of over 69% compared to $102.7 million in the same quarter of the previous year. This strong sales …
This represents a slight widening of losses from the previous year's figure of $0.05 per share. The company is grappling with share price declines, with shares down 7.2% year-to-date and 14.7% over the past month. Ocugen's current market capitalization stands at approximately $434 million, …
This loss marks an increase compared to the $7.4 million incurred during the same period in 2025. Despite falling short of a $0.14 consensus estimate for the quarter, the company aims to bolster investor confidence through its advancing pipeline of gene therapies. The results …
Oscar Health, Inc. has recorded a significant milestone in its financial performance, reporting an earnings per share (EPS) of $1.10 for the quarter ending June 30, vastly exceeding the $0.39 consensus estimate. The surge in profitability reflects Oscar’s strategic initiatives and recovery in the …
This change comes after the recruitment of patients in the 10 mg/kg cohort and reflects a proactive response to safety data from ongoing trials.
Praxis Precision Medicines, Inc. (NASDAQ: PRAX) has reported a narrower net loss for the second quarter of 2026, posting an EPS of $-2.87 compared to a consensus estimate of $-3.73. The decrease in losses highlights potential investor confidence amid a competitive environment, suggesting that …
Precision BioSciences, Inc. (NASDAQ: DTIL) announced a second-quarter EPS of $-0.75, falling short of the $-0.67 consensus estimate, highlighting challenges in its path to profitability. This result contrasts the strong performance of the previous quarter, where the company faced an uphill battle in securing …
Prime Medicine, Inc. (NASDAQ: PRME) reported a second-quarter earnings per share (EPS) of $-0.24, a slight increase compared to the $-0.26 consensus estimate. The announcement on August 6, 2026, underscored the company's emphasis on advancing its innovative gene therapies. PRME reported a net loss …
Privia Health Group, Inc. (NASDAQ: PRVA) reported a compelling net income of $9.0 million for the second quarter of 2026, representing a remarkable increase of 236.7% compared to the same period last year. This acceleration in profitability aligns with the consensus EPS estimate of …
Please wait processing your request...